Moody Lynn & Lieberson LLC Has $1.97 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Moody Lynn & Lieberson LLC increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 334.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,307 shares of the biopharmaceutical company’s stock after purchasing an additional 16,397 shares during the period. Moody Lynn & Lieberson LLC’s holdings in Gilead Sciences were worth $1,968,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GILD. Advocate Group LLC lifted its position in shares of Gilead Sciences by 1.0% during the 4th quarter. Advocate Group LLC now owns 79,445 shares of the biopharmaceutical company’s stock worth $7,338,000 after buying an additional 751 shares during the period. AEGON ASSET MANAGEMENT UK Plc boosted its stake in shares of Gilead Sciences by 2.7% in the 4th quarter. AEGON ASSET MANAGEMENT UK Plc now owns 267,474 shares of the biopharmaceutical company’s stock valued at $24,701,000 after purchasing an additional 6,968 shares in the last quarter. Grimes & Company Inc. boosted its stake in shares of Gilead Sciences by 0.9% in the 4th quarter. Grimes & Company Inc. now owns 179,429 shares of the biopharmaceutical company’s stock valued at $16,574,000 after purchasing an additional 1,535 shares in the last quarter. SJS Investment Consulting Inc. grew its holdings in shares of Gilead Sciences by 266.5% in the 4th quarter. SJS Investment Consulting Inc. now owns 788 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 573 shares during the last quarter. Finally, Linden Thomas Advisory Services LLC increased its position in shares of Gilead Sciences by 3.8% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 44,531 shares of the biopharmaceutical company’s stock worth $4,113,000 after purchasing an additional 1,630 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 0.2 %

Shares of NASDAQ GILD opened at $93.07 on Friday. The firm has a 50 day moving average price of $91.74 and a 200 day moving average price of $84.86. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The stock has a market cap of $115.99 billion, a P/E ratio of 1,034.11, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.29 EPS. Analysts expect that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were given a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Analysts Set New Price Targets

A number of research firms have commented on GILD. Daiwa America upgraded shares of Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Robert W. Baird boosted their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Citigroup started coverage on Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 price objective on the stock. Finally, Wells Fargo & Company lifted their price target on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $97.96.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 in the last 90 days. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.